Comanor and Scherer Revisited: Do Patents Proxy for New Product Introductions?
Stuart J. H. Graham
Georgia Institute of Technology - Scheller College of Business; Office of Chief Economist, United States Patent and Trademark Office
Matthew John Higgins
Georgia Institute of Technology
September 24, 2007
In this paper, we examine the propriety of using patents as a proxy for firm innovative performance. We find that in the pharmaceutical industry during 1985-2001 they are not. Replicating the methodology in a study by Comanor and Scherer (1969) upon which many current studies base their use of patents as proxy, we demonstrate simple correlations of 0.1911 between lagged-patent filings and actual new product introductions, and partial correlations of 0.1785 when holding firm size constant. Our results raise serious questions about the usefulness of employing patent measures in contemporary studies that examine the innovative performance of firms.
Number of Pages in PDF File: 14
Keywords: Patenting; Pharmaceutical industry; Research productivity
JEL Classification: O30working papers series
Date posted: October 25, 2007
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo6 in 0.328 seconds